Sponges against miR-19 and miR-155 reactivate the p53-Socs1 axis in hematopoietic cancers

Cytokine

Volumn 82, Issue , 2016, Pages 80-86

  Mignacca, Lian ^a   Saint Germain, Emmanuelle ^a   Benoit, Alexandre ^a   Bourdeau, Véronique ^a   Moro, Alejandro ^a   Ferbeyre, Gerardo ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Catalytic sponges; miR 155; miR 19; miRNA sponges; p53; SOCS1

Indexed keywords

DOXORUBICIN; MICRORNA; MICRORNA 155; MICRORNA 19; PROTEIN P53; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG; HAMMERHEAD RIBOZYME; MIRN155 MICRORNA, HUMAN; MIRN155 MICRORNA, MOUSE; MIRN19 MICRORNA, HUMAN; MIRN19 MICRORNA, MOUSE; RIBOZYME; RNA; SOCS1 PROTEIN, HUMAN; SOCS1 PROTEIN, MOUSE; TP53 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CANCER GROWTH; CELL MIGRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; GENE ACTIVITY; GENE FUNCTION; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; MYELOMA CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAW 264.7 CELL LINE; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENETICS; LEUKEMIA; METABOLISM; MULTIPLE MYELOMA;

ANIMALS; HUMANS; LEUKEMIA; MICE; MICRORNAS; MULTIPLE MYELOMA; RAW 264.7 CELLS; RNA, CATALYTIC; RNA, NEOPLASM; SUPPRESSOR OF CYTOKINE SIGNALING 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84960192754     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.01.015     Document Type: Article

References (33)

1. Ferbeyre G., Moriggl R. The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim. Biophys. Acta. 2011, 1815:104-114.
2. Marcucci G., Mrozek K., Radmacher M.D., Garzon R., Bloomfield C.D. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2010.
3. Chen J., Odenike O., Rowley J.D. Leukaemogenesis: more than mutant genes. Nat. Rev. Cancer. 2010, 10:23-36.
4. Ilangumaran S., Rottapel R. Regulation of cytokine receptor signaling by SOCS1. Immunol. Rev. 2003, 192:196-211.
5. Calabrese V., Mallette F.A., Deschenes-Simard X., Ramanathan S., Gagnon J., Moores A., et al. SOCS1 links cytokine signaling to p53 and senescence. Mol. Cell. 2009, 36:754-767.
6. Mallette F.A., Calabrese V., Ilangumaran S., Ferbeyre G. SOCS1, a novel interaction partner of p53 controlling oncogene-induced senescence. Aging (Albany NY) 2010, 2:445-452.
7. Bouamar H., Jiang D., Wang L., Lin A.P., Ortega M., Aguiar R.C. MicroRNA 155 control of p53 activity is context dependent and mediated by Aicda and Socs1. Mol. Cell. Biol. 2015, 35:1329-1340.
8. Shimada K., Serada S., Fujimoto M., Nomura S., Nakatsuka R., Harada E., et al. Molecular mechanism underlying the antiproliferative effect of suppressor of cytokine signaling-1 in non-small-cell lung cancer cells. Cancer Sci. 2013, 104:1483-1491.
9. Hatirnaz O., Ure U., Ar C., Akyerli C., Soysal T., Ferhanoglu B., et al. The SOCS-1 gene methylation in chronic myeloid leukemia patients. Am. J. Hematol. 2007, 82:729-730.
10. Ekmekci C.G., Gutierrez M.I., Siraj A.K., Ozbek U., Bhatia K. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am. J. Hematol. 2004, 77:233-240.
11. Chim C.S., Wong K.Y., Loong F., Srivastava G. SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia 2004, 18:356-358.
12. Liu T.C., Lin S.F., Chang J.G., Yang M.Y., Hung S.Y., Chang C.S. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br. J. Haematol. 2003, 123:654-661.
13. Lu L.F., Thai T.H., Calado D.P., Chaudhry A., Kubo M., Tanaka K., et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009, 30:80-91.
14. Jiang S., Zhang H.W., Lu M.H., He X.H., Li Y., Gu H., et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010, 70:3119-3127.
15. Merkel O., Hamacher F., Griessl R., Grabner L., Schiefer A.I., Prutsch N., et al. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. J. Pathol. 2015, 236:445-456.
16. Pichiorri F., Suh S.S., Ladetto M., Kuehl M., Palumbo T., Drandi D., et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc. Natl. Acad. Sci. U S A 2008, 105:12885-12890.
17. Kobayashi N., Uemura H., Nagahama K., Okudela K., Furuya M., Ino Y., et al. Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget 2012, 3:1455-1471.
18. Mallette F.A., Gaumont-Leclerc M.F., Huot G., Ferbeyre G. Myc down-regulation as a mechanism to activate the Rb pathway in STAT5A-induced senescence. J. Biol. Chem. 2007, 282:34938-34944.
19. Kluiver J., Gibcus J.H., Hettinga C., Adema A., Richter M.K., Halsema N., et al. Rapid generation of microRNA sponges for microRNA inhibition. PLoS ONE 2012, 7:e29275.
20. Brummelkamp T.R., Bernards R., Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296:550-553.
21. Ferbeyre G., de Stanchina E., Querido E., Baptiste N., Prives C., Lowe S.W. PML is induced by oncogenic ras and promotes premature senescence. Genes. Dev. 2000, 14:2015-2027.
22. Mallette F.A., Moiseeva O., Calabrese V., Mao B., Gaumont-Leclerc M.F., Ferbeyre G. Transcriptome analysis and tumor suppressor requirements of STAT5-induced senescence. Ann. N Y Acad. Sci. 2010, 1197:142-151.
23. Deschenes-Simard X., Gaumont-Leclerc M.F., Bourdeau V., Lessard F., Moiseeva O., Forest V., et al. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes. Dev. 2013, 27:900-915.
24. Luo X.Z.J., Wang H., Du Y., Yang L., Zheng F., Ma D. PolyA RT-PCR-based quantification of microRNA by using universal TaqMan probe. Biotechnol. Lett. 2012, 34:627-633.
25. Lokuta M.A., McDowell M.A., Paulnock D.M. Identification of an additional isoform of STAT5 expressed in immature macrophages. J. Immunol. 1998, 161:1594-1597.
26. Kopp K.L., Ralfkiaer U., Gjerdrum L.M., Helvad R., Pedersen I.H., Litman T., et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle 2013, 12:1939-1947. (Georgetown, Tex.).
27. Feuermann Y., Robinson G.W., Zhu B.M., Kang K., Raviv N., Yamaji D., et al. The miR-17/92 cluster is targeted by STAT5 but dispensable for mammary development. Genesis 2012, 50:665-671.
28. Purvis J.E., Karhohs K.W., Mock C., Batchelor E., Loewer A., Lahav G. P53 dynamics control cell fate. Science 2012, 336:1440-1444.
29. Behm-Ansmant I., Rehwinkel J., Doerks T., Stark A., Bork P., Izaurralde E. MRNA degradation by miRNAs and GW182 requires both CCR4:NOT deadenylase and DCP1:DCP2 decapping complexes. Genes. Dev. 2006, 20:1885-1898.
30. Lambert G.K., Duhme-Klair A.K., Morgan T., Ramjee M.K. The background, discovery and clinical development of BCR-ABL inhibitors. Drug Discov. Today 2013, 18:992-1000.
31. Lujambio A., Lowe S.W. The microcosmos of cancer. Nature 2012, 482:347-355.
32. Marcucci G., Mrozek K., Radmacher M.D., Garzon R., Bloomfield C.D. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011, 117:1121-1129.
33. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., et al. Treatment of HCV infection by targeting microRNA. N Engl. J. Med. 2013, 368:1685-1694.